Lynn Seely (Myovant)

Lynn Seely hits the ex­it as My­ovant grad­u­ates to com­mer­cial space — hand­ing the reins to Am­gen vet

When Lynn Seely took the helm at My­ovant as the new­ly-re­tired chief med­ical of­fi­cer of Medi­va­tion, the biotech was still a fledg­ling mem­ber of Vivek Ra­maswamy’s sprawl­ing Vant fam­i­ly, prepar­ing to take flight with a Phase III drug from Take­da. Four and a half years lat­er, every­thing has changed: My­ovant’s largest share­hold­er is now Japan­ese phar­ma Sum­it­o­mo Dainip­pon, and in just the past month, the FDA hand­ed re­l­u­golix its first ap­proval and Pfiz­er has en­gi­neered a $4.2 bil­lion com­mer­cial part­ner­ship.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.